Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331415 | 0.93 | KDM4C (0.36) | KDM4CALDH1A1LMNA | |
| SCHEMBL4216974 | 0.73 | — | — | |
| SCHEMBL331416 | 0.72 | KDM4C (0.40) | KDM4CALDH1A1LMNA | |
| SCHEMBL332684 | 0.72 | KDM4C (0.40) | KDM4CALDH1A1LMNA | |
| SCHEMBL27642437 | 0.67 | KDM4C (0.54) | KDM4CALDH1A1LMNA | |
| SCHEMBL4038517 | 0.66 | KDM4C (0.56) | KDM4CALDH1A1LMNA | |
| SCHEMBL331623 | 0.63 | KDM4C (0.61) | KDM4CALDH1A1LMNA | |
| SCHEMBL332682 | 0.62 | POLB (0.32) | ALDH1A1 | |
| SCHEMBL16919030 | 0.62 | KDM4C (0.62) | KDM4CALDH1A1LMNA | |
| SCHEMBL7254882 | 0.61 | KDM4C (0.53) | KDM4CALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1689751-A1 | 5,7-DIAMINOPYRAZOLO¬4,3-D|PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | Pfizer Limited (GB) | 2006-08-16 | — | — | EP | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | KDM4C 3970/4885ALDH1A1 851/4885LMNA 4275/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | KDM4C 3970/4885ALDH1A1 851/4885LMNA 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.